Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XY066 is an oral immediate-release fixed-dose capsule developed by Changchun Haiyue Pharmaceutical that contains esomeprazole 20 mg and sodium bicarbonate 1100 mg. Esomeprazole is a proton-pump inhibitor that irreversibly inhibits the gastric hydrogen-potassium ATPase in parietal cells, suppressing gastric acid secretion. Sodium bicarbonate rapidly neutralizes gastric acid and raises intragastric pH, protecting acid-labile esomeprazole from degradation and enabling immediate release without an enteric coating. The product was studied against delayed-release esomeprazole for pharmacokinetic and pharmacodynamic bioequivalence in healthy Chinese adults, with intended uses including gastroesophageal reflux disease and Helicobacter pylori eradication when combined with appropriate antibacterial therapy. ([chinadrugtrials.org.cn](https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=b987072feef6499c9361590dd60052ed))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esomeprazole + sodium bicarbonate (Changchun Haiyue Pharmaceutical).